Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Canada
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
53
PharmaCompass offers a list of Granisetron API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Granisetron manufacturer or Granisetron supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Granisetron manufacturer or Granisetron supplier.
PharmaCompass also assists you with knowing the Granisetron API Price utilized in the formulation of products. Granisetron API Price is not always fixed or binding as the Granisetron Price is obtained through a variety of data sources. The Granisetron Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A [3H]-BRL-43694 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of [3H]-BRL-43694, including repackagers and relabelers. The FDA regulates [3H]-BRL-43694 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. [3H]-BRL-43694 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of [3H]-BRL-43694 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A [3H]-BRL-43694 supplier is an individual or a company that provides [3H]-BRL-43694 active pharmaceutical ingredient (API) or [3H]-BRL-43694 finished formulations upon request. The [3H]-BRL-43694 suppliers may include [3H]-BRL-43694 API manufacturers, exporters, distributors and traders.
click here to find a list of [3H]-BRL-43694 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A [3H]-BRL-43694 DMF (Drug Master File) is a document detailing the whole manufacturing process of [3H]-BRL-43694 active pharmaceutical ingredient (API) in detail. Different forms of [3H]-BRL-43694 DMFs exist exist since differing nations have different regulations, such as [3H]-BRL-43694 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A [3H]-BRL-43694 DMF submitted to regulatory agencies in the US is known as a USDMF. [3H]-BRL-43694 USDMF includes data on [3H]-BRL-43694's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The [3H]-BRL-43694 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of [3H]-BRL-43694 suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a [3H]-BRL-43694 Drug Master File in Korea ([3H]-BRL-43694 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of [3H]-BRL-43694. The MFDS reviews the [3H]-BRL-43694 KDMF as part of the drug registration process and uses the information provided in the [3H]-BRL-43694 KDMF to evaluate the safety and efficacy of the drug.
After submitting a [3H]-BRL-43694 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their [3H]-BRL-43694 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of [3H]-BRL-43694 suppliers with KDMF on PharmaCompass.
A [3H]-BRL-43694 written confirmation ([3H]-BRL-43694 WC) is an official document issued by a regulatory agency to a [3H]-BRL-43694 manufacturer, verifying that the manufacturing facility of a [3H]-BRL-43694 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting [3H]-BRL-43694 APIs or [3H]-BRL-43694 finished pharmaceutical products to another nation, regulatory agencies frequently require a [3H]-BRL-43694 WC (written confirmation) as part of the regulatory process.
click here to find a list of [3H]-BRL-43694 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing [3H]-BRL-43694 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for [3H]-BRL-43694 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture [3H]-BRL-43694 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain [3H]-BRL-43694 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a [3H]-BRL-43694 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of [3H]-BRL-43694 suppliers with NDC on PharmaCompass.
[3H]-BRL-43694 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of [3H]-BRL-43694 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right [3H]-BRL-43694 GMP manufacturer or [3H]-BRL-43694 GMP API supplier for your needs.
A [3H]-BRL-43694 CoA (Certificate of Analysis) is a formal document that attests to [3H]-BRL-43694's compliance with [3H]-BRL-43694 specifications and serves as a tool for batch-level quality control.
[3H]-BRL-43694 CoA mostly includes findings from lab analyses of a specific batch. For each [3H]-BRL-43694 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
[3H]-BRL-43694 may be tested according to a variety of international standards, such as European Pharmacopoeia ([3H]-BRL-43694 EP), [3H]-BRL-43694 JP (Japanese Pharmacopeia) and the US Pharmacopoeia ([3H]-BRL-43694 USP).
